Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martina Smolić is active.

Publication


Featured researches published by Martina Smolić.


Journal of clinical and translational hepatology | 2016

Hepatitis C virus, insulin resistance, and steatosis

Dominik Kralj; Lucija Virović Jukić; Sanja Stojsavljević; Marko Duvnjak; Martina Smolić; Ines Bilić Čurčić

Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide. Liver steatosis is a common finding in many hepatic and extrahepatic disorders, the most common being metabolic syndrome (MS). Over time, it has been shown that the frequent coexistence of these two conditions is not coincidental, since many epidemiological, clinical, and experimental studies have indicated HCV to be strongly associated with liver steatosis and numerous metabolic derangements. Here, we present an overview of publications that provide clinical evidence of the metabolic effects of HCV and summarize the available data on the pathogenetic mechanisms of this association. It has been shown that HCV infection can induce insulin resistance (IR) in the liver and peripheral tissues through multiple mechanisms. Substantial research has suggested that HCV interferes with insulin signaling both directly and indirectly, inducing the production of several proinflammatory cytokines. HCV replication, assembly, and release from hepatocytes require close interactions with lipid droplets and host lipoproteins. This modulation of lipid metabolism in host cells can induce hepatic steatosis, which is more pronounced in patients with HCV genotype 3. The risk of steatosis depends on several viral factors (including genotype, viral load, and gene mutations) and host features (visceral obesity, type 2 diabetes mellitus, genetic predisposition, medication use, and alcohol consumption). HCV-related IR and steatosis have been shown to have a remarkable clinical impact on the prognosis of HCV infection and quality of life, due to their association with resistance to antiviral therapy, progression of hepatic fibrosis, and development of hepatocellular carcinoma. Finally, HCV-induced IR, oxidative stress, and changes in lipid and iron metabolism lead to glucose intolerance, arterial hypertension, hyperuricemia, and atherosclerosis, resulting in increased cardiovascular mortality.


International Journal of Environmental Research and Public Health | 2017

Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis

Tomislav Kizivat; Martina Smolić; Ivana Marić; Maja Tolušić Levak; Robert Smolić; Ines Bilić Čurčić; Lucija Kuna; Ivan Mihaljević; Aleksandar Včev; Sandra Tucak-Zorić

Urolithiasis is characterized by the formation and retention of solid crystals within the urinary tract. Kidney stones are mostly composed of calcium oxalate, which predominantly generates free radicals that are toxic to renal tubular cells. The aim of the study is to explore possible effects of antioxidant pre-treatment on inhibition of oxidative stress. Three cell lines were used as in vitro model of urolithiasis: MDCK I, MDCK II and LLC-PK1. Oxidative stress was induced by exposure of cells to sodium oxalate in concentration of 8 mM. In order to prevent oxidative stress, cells were pre-treated with three different concentrations of l-arginine and vitamin E. Oxidative stress was evaluated by determining the expression of superoxide dismutase (SOD), osteopontin (OPN), and by the concentration of glutathione (GSH). In all three cell lines, pre-treatment of antioxidants increased cell survival. Positive correlation of SOD and OPN expression as well as GSH concentration was observed in all groups of cells. Our results indicate that an antioxidant pre-treatment with l-arginine and vitamin E is able to hamper oxalate-induced oxidative stress in kidney epithelial cells and as such could play a role in prevention of urolithiasis.


Journal of clinical and translational hepatology | 2013

Update on the Development of Anti-Viral Agents Against Hepatitis C.

Kristin Loening MacArthur; Robert Smolić; Martina Smolić; Cathy H. Wu; George Y. Wu

Hepatitis C virus (HCV) infects nearly 170 million people worldwide and causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The search for a drug regimen that maximizes efficacy and minimizes side effects is quickly evolving. This review will discuss a wide range of drug targets currently in all phases of development for the treatment of HCV. Direct data from agents in phase III/IV clinical trials will be presented, along with reported side-effect profiles. The mechanism of action of all treatments and resistance issues are highlighted. Special attention is given to available trial data supporting interferon-free treatment regimens. HCV has become an increasingly important public health concern, and it is important for physicians to stay up to date on the rapidly growing novel therapeutic options.


Journal of Clinical Medicine | 2018

Primary Care Provider Counseling Practices about Adverse Drug Reactions and Interactions in Croatia

Nikola Raguz Lucic; Jelena Jakab; Martina Smolić; Ana-Maria Milas; Tea Omanović Kolarić; Vjera Nincevic; Kristina Bojanic; Kristina Kralik; Maja Miškulin; George Y. Wu; Robert Smolić

Background: Prescribing medications is one of the most common medical decisions that is made by primary care providers (PCPs). In the Republic of Croatia, PCPs hold a key position in prescribing and evaluating the medications that are provided for patients. Accordingly, providing advice for patients regarding the potential adverse drug reactions (ADRs) and drug-drug interactions (DDIs) is frequently the responsibility of the PCPs. The aim of the current study was to assess the knowledge, attitudes, and counseling practices of PCPs regarding drug interactions and adverse effects. Methods: After enrolling 195 PCPs that were selected at random, a survey was conducted while using an anonymous questionnaire that was created based on previously published studies, adjusted in a way that includes the most commonly prescribed medications in Croatia. Results: Of the 10 questions on knowledge about DDIs and ADRs, the median number of correct responses by PCPs was 5 (interquartile range 4 to 7). More than half of respondents (56%) agreed with the claim that knowledge of drug side effects facilitated their work in family medicine. Almost all of the respondents (92.8%) explained side effects and drug interactions to special groups of patients (pregnant women, elderly patients etc.). Conclusion: The results show a need for additional education in the field of drug prescribing. However, PCPs were aware of the importance of counseling practices about adverse drug reactions and interactions and counseling practices among special patients populations are satisfactory.


Journal of Clinical Medicine | 2018

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy

Kristina Bojanic; Ines Bilić Čurčić; Lucija Kuna; Tomislav Kizivat; Robert Smolić; Nikola Raguž Lučič; Kristina Kralik; Vatroslav Šerić; Gordana Ivanac; Sandra Tucak-Zorić; Aleksandar Včev; Martina Smolić

Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters. Methods: 137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual-energy X-ray absorptiometry (DXA). Lifestyle factors were investigated by a self-reported questionnaire. Results: Sclerostin was significantly higher in the AI-treated group (31.8 pmol/L vs. 24.1 pmol/L; p < 0.001), whereas DKK1 was significantly lower in the AI-treated group (24.3 pmol/L vs. 26.02 pmol/L; p < 0.001). Total hip and femoral neck BMD were significantly lower in the AI-treated group. Conclusion: AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1.


International Journal of Environmental Research and Public Health | 2018

Psoriasis Severity—A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome

Melita Vukšić Polić; Maja Miškulin; Martina Smolić; Kristina Kralik; Ivan Miškulin; Maja Cigrovski Berkovic; Ines Bilić Čurčić

Background: It is still debatable whether psoriasis increases cardiovascular risk indirectly since it is associated with metabolic syndrome or is an independent cardiovascular risk factor. The aim of this study was to evaluate psoriasis severity as an independent predictor of insulin resistance (IR) irrespective of the presence of metabolic syndrome (MetS). Methods: This was a case control study including 128 patients stratified into two groups: patients with psoriasis and metabolic syndrome vs. patients with psoriasis and no metabolic syndrome. MetS was diagnosed according to ATP III criteria with homeostatic model assessment of insulin resistance (HOMA-IR), as well as a homeostatic model assessment of beta cell function (HOMA-β) were calculated. Results: Compared to subjects without metabolic syndrome, patients with metabolic syndrome had a significantly higher Psoriasis Area Severity Index (PASI) values (p < 0.001). The strongest correlation was established for HOMA-IR and the PASI index (p < 0.001), even after adjustment for body mass index (BMI) in regression analysis model. In patients without MetS and severe forms of disease, the HOMA-IR and HOMA-β values were significantly higher compared to mild forms of disease (p < 0.001 for all) while in subjects with MetS no difference was established for HOMA-IR or HOMA-β based on disease severity. Conclusions: Psoriasis severity is an independent risk factor of HOMA-IR, the strongest association being present in the non-MetS group, who still had preserved beta cell function suggesting direct promotion of atherosclerosis via insulin resistance depending on the disease severity, but irrespective of the presence of metabolic syndrome.


Current Drug Metabolism | 2018

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives

Lucija Kuna; Ivana Bozic; Tomislav Kizivat; Kristina Bojanic; Margareta Mršo; Edgar Kralj; Robert Smolić; George Y. Wu; Martina Smolić

Background: Drug-induced Liver Injury (DILI) is an important cause of acute liver failure cases in the United States, and remains a common cause of withdrawal of drugs in both preclinical and clinical phases. Methods: A structured search of bibliographic databases – Web of Science Core Collection, Scopus and Medline for peer-reviewed articles on models of DILI was performed. The reference lists of relevant studies was prepared and a citation search for the included studies was carried out. In addition, the characteristics of screened studies were described. Results: One hundred and six articles about the existing knowledge of appropriate models to study DILI in vitro and in vivo with special focus on hepatic cell models, variations of 3D co-cultures, animal models, databases and predictive modeling and translational biomarkers developed to understand the mechanisms and pathophysiology of DILI are described. Conclusion: Besides descriptions of current applications of existing modeling systems, associated advantages and limitations of each modeling system and future directions for research development are discussed as well.


Archive | 2015

Current Management and Novel Therapeutic Strategies to Combat Chronic Delta Hepatitis

Hrvoje Roguljić; Sonja Sarcevic; Robert Smolić; Aleksandar Vcev Nikola Raguz Lucic; Martina Smolić

HDV is an unusal, defective hepatotropic virus which causes severe acute hepatitis and most progressive chronic viral hepatitis. Despite the efforts in eradication of HDV, as its obligatory helper HBV, prevalence of HDV in developed countries remains stable and represents a relevant public health concern. Current conventional therapy of hepatitis delta is characterized with poor overall response, thus further investigations of novel treatment options are needed. Continuous research of virology and pathogenesis is necessary to provide fundamentals for development of novel approaches in treatment of HDV.


Journal of Digestive Diseases | 2012

Pharmacogenetic selection of transplanted human hepatocytes in immunocompetent rats

Martina Smolić; Catherine H. Wu; Shilpa Madadi; Nidhi Gupta; Robert Smolić; Marcy Coash; Jeanette Smith; George Y. Wu

To introduce a genetic survival advantage for transplanted human hepatocytes over host cells in rats.


Anti-inflammatory & anti-allergy agents in medicinal chemistry | 2010

Mn-SOD and Chronic Inflammation of Gastric Mucosa

Jasna Dovhanj; Dražen Švagelj; Martina Smolić; Robert Smolić; Ivana Marić

The involvement of reactive oxygen species in the inflammatory tissue destruction is well known. Significant changes in the activity and expression of several isoforms of superoxide dismutase were observed in the human gastric disease. Mn-SOD attracted the attention of researchers because of its inducibility by oxidative stress. There is increasing evidence that oxidative stress plays a role in the progression of mucosal damage leading to gastric cancer. The evaluation of possible modulation of Mn-SOD activity during chronic inflammation of gastric mucosa could reveal whether its assessment is important to prevent the accumulation of gastric epithelial cell damage and thereby reduce the risk of gastric carcinoma.

Collaboration


Dive into the Martina Smolić's collaboration.

Top Co-Authors

Avatar

Robert Smolić

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

Aleksandar Včev

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar

Tomislav Kizivat

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar

Lucija Kuna

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar

Antun Tucak

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar

Ines Bilic-Curcic

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

George Y. Wu

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

Jasminka Milas-Ahić

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Top Co-Authors

Avatar

Ivan Mihaljević

Josip Juraj Strossmayer University of Osijek

View shared research outputs
Researchain Logo
Decentralizing Knowledge